Lung adenocarcinoma harboring the c-ros oncogene 1 (ROS1) translocations represents a newly discovered molecular subset of non small cell lung cancer (NSCLC. Just as with anaplastic lymphoma receptor tyrosine kinase (ALK)-rearranged NSCLC, early phase clinical trials have shown a high response rate to crizotinib in these patients. Fluorescent in situ hybridization (FISH) is considered the reference standard for detecting ROS1 translocations and ALK rearrangements. Several anti-ROS1 antibodies are in Use, and the first results have suggested that immunohistochemistry (IHC) Mild, be a suitable tool for identifying ROS1 rearrangement. The results from this small series suggest that IHC is a valuable tool, for identifying ROS1 rearrangement and have confirmed that this Subset of patients can benefit from crizotinib-based treatment.
Dramatic Response to Crizotinib in ROS1 Fluorescent In Situ Hybridization- and Immunohistochemistry-Positive Lung Adenocarcinoma: A Case Series
CRINO', Lucio
2014
Abstract
Lung adenocarcinoma harboring the c-ros oncogene 1 (ROS1) translocations represents a newly discovered molecular subset of non small cell lung cancer (NSCLC. Just as with anaplastic lymphoma receptor tyrosine kinase (ALK)-rearranged NSCLC, early phase clinical trials have shown a high response rate to crizotinib in these patients. Fluorescent in situ hybridization (FISH) is considered the reference standard for detecting ROS1 translocations and ALK rearrangements. Several anti-ROS1 antibodies are in Use, and the first results have suggested that immunohistochemistry (IHC) Mild, be a suitable tool for identifying ROS1 rearrangement. The results from this small series suggest that IHC is a valuable tool, for identifying ROS1 rearrangement and have confirmed that this Subset of patients can benefit from crizotinib-based treatment.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
